Indiana Verified Parameters SKU: N/A
VASOGLOR 90 MG TABLET
90mg Tablet
Brand / Label: Vasoglor
| Generic Composition | Ticagrelor |
| Manufacturer | Glenmark Pharmaceuticals Ltd |
| Packaging Metrics | 10 |
| Administration Route | Oral |
| Regulatory Schedule | Schedule H Prescription Drug |
Quick Clinical Insights Summary
VASOGLOR 90 MG TABLET contains Ticagrelor 90 mg, a prescription antiplatelet medicine used to help prevent blood clot formation in patients with Acute Coronary Syndrome (ACS), after coronary angioplasty (PCI) with stent placement, or in those at high risk of heart attack or stroke. It works by inhibiting platelet aggregation, reducing the likelihood of clots that can block blood flow to the heart or brain.
VASOGLOR 90 MG TABLET is commonly prescribed alongside low-dose aspirin (75–100 mg) as part of dual antiplatelet therapy (DAPT). It should be taken exactly as directed by your cardiologist and should not be stopped abruptly, especially after stent implantation, as this may increase the risk of serious cardiovascular events.
Key Benefits:
Helps prevent recurrent heart attacks.
Reduces the risk of stroke.
Prevents blood clot formation after coronary stent placement.
Used in the management of Acute Coronary Syndrome (ACS).
Fast-acting antiplatelet medication with reversible platelet inhibition.
Active Ingredient: Ticagrelor 90 mg
Drug Class: Antiplatelet Agent (P2Y12 Receptor Inhibitor)
Prescription Status: Prescription Required (Rx)
Disclaimer: VASOGLOR 90 MG TABLET should be used only under the supervision of a qualified healthcare professional. Follow your doctor's instructions carefully and report any unusual bleeding, persistent shortness of breath, or other concerning symptoms promptly. Never discontinue the medication without consulting your physician.
Common Treatment Indications
Acute Coronary Syndrome (ACS), Heart Attack (MI), STEMI, NSTEMI, Unstable Angina, Coronary Artery Disease (CAD), Post Angioplasty (PCI), After Coronary Stent Placement, Prevention of Heart Attack, Prevention of Stroke, Blood Clot Prevention, Dual Antiplatelet Therapy (DAPT)
Active Composition Profile
Ticagrelor 90mg
Standard Clinical Dosage Guideline
Take at the same time every day.
Can be taken with or without food.
Swallow whole with water.
Do not stop the medicine on your own, especially if you have a coronary stent, as stopping suddenly can increase the risk of heart attack or stent thrombosis.
Prevent heart attack recurrence.
Reduce the risk of stroke.
Prevent blood clot formation after angioplasty (stent placement).
Treat patients with Acute Coronary Syndrome (heart attack or unstable angina).
Key Therapeutic Benefits
VASOGLOR 90 MG TABLET (Ticagrelor 90 mg) helps protect the heart and blood vessels by preventing platelets from forming harmful blood clots. When taken as prescribed, it offers the following benefits:
Helps reduce the risk of heart attack (myocardial infarction).
Lowers the risk of stroke caused by blood clots.
Prevents blood clot formation in coronary arteries and stents.
Helps keep coronary stents open after angioplasty (PCI).
Reduces the risk of cardiovascular death in patients with Acute Coronary Syndrome (ACS).
Provides rapid and effective platelet inhibition to reduce thrombotic events.
Helps prevent recurrent heart attacks in high-risk patients.
Supports long-term management of coronary artery disease (CAD) when used as prescribed.
Commonly used as part of Dual Antiplatelet Therapy (DAPT) with low-dose aspirin for enhanced cardiovascular protection.
Mechanism of Action (How it works)
VASOGLOR 90 MG TABLET contains Ticagrelor 90 mg, a reversible, direct-acting P2Y12 receptor antagonist. It works by selectively blocking the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets, preventing ADP-induced platelet activation and aggregation. This reduces the formation of harmful blood clots within the arteries, helping to lower the risk of heart attack, stroke, and stent thrombosis. Unlike some other antiplatelet medicines, ticagrelor does not require metabolic activation, resulting in a rapid onset of antiplatelet effect.
Directions For Proper Administration
Take VASOGLOR 90 MG TABLET exactly as prescribed by your doctor.
Swallow the tablet whole with a glass of water. Do not chew, crush, or break it unless your doctor specifically advises otherwise.
It can be taken with or without food.
Take the medicine at the same times every day to maintain a consistent level in your body and improve effectiveness.
If prescribed after a heart attack or coronary stent placement, it is commonly used together with low-dose aspirin (75–100 mg daily) as directed by your cardiologist.
If you miss a dose, take the next scheduled dose at the usual time. Do not take a double dose to make up for a missed dose.
Do not stop taking VASOGLOR 90 MG TABLET without consulting your doctor, as sudden discontinuation may increase the risk of heart attack, stroke, or blood clot formation, especially after stent implantation.
If you have difficulty swallowing, the tablet may be crushed, mixed with water, and taken immediately, but only if advised by your healthcare provider.
General Warnings
Use only under the supervision of a qualified healthcare professional.
Do not discontinue the medication without consulting your doctor, especially after coronary stent placement.
Increases the risk of bleeding, including serious or life-threatening bleeding.
Inform your doctor before any surgery, dental procedure, or invasive intervention.
Report unusual bruising, prolonged bleeding, blood in urine or stools, or persistent shortness of breath.
Usually prescribed together with low-dose aspirin (75–100 mg/day). Higher aspirin doses may reduce ticagrelor's effectiveness.
Contraindications
Do not use if you have:
Hypersensitivity to Ticagrelor or any ingredient.
Active pathological bleeding.
History of intracranial (brain) hemorrhage.
Severe hepatic impairment.
Concurrent use with strong CYP3A4 inhibitors when contraindicated.
Drug-Drug Interactions
Major Interactions
Ketoconazole
Itraconazole
Clarithromycin
Ritonavir
Cobicistat
Moderate Interactions
Rifampicin
Carbamazepine
Phenytoin
Phenobarbital
Digoxin
Simvastatin (>40 mg)
Lovastatin (>40 mg)
Increased Bleeding Risk With
Warfarin
Heparin
Apixaban
Rivaroxaban
Dabigatran
Aspirin (high doses)
Clopidogrel
Prasugrel
NSAIDs (Ibuprofen, Diclofenac, Naproxen)
Side Effects Profile
Common: Easy bruising Nosebleeds Bleeding gums Mild bleeding from cuts Shortness of breath (Dyspnea) Dizziness Headache Nausea Diarrhea
Serious Clinical Indicators: Severe or uncontrolled bleeding Gastrointestinal bleeding Intracranial hemorrhage Blood in urine Vomiting blood Black or tarry stools Severe allergic reaction Significant bradycardia or heart rhythm disturbances Persistent or severe shortness of breath
Dietary/Food Matrix Constraints
Can be taken with or without food. Avoid excessive grapefruit or grapefruit juice, as it may increase Ticagrelor levels. Maintain a heart-healthy, low-fat, low-salt diet as advised by your healthcare provider.
Physiological Adjustments & Cohort Profiling
| Pregnancy | Lactation | Pediatric Cohorts | Geriatric Cohorts |
|---|---|---|---|
| Pregnancy Category: Use only if clearly needed and prescribed by a physician. Human safety data are limited. Use only when the expected benefit outweighs potential fetal risks. | It is not known whether Ticagrelor passes into human breast milk. Breastfeeding should be undertaken only after medical consultation. Alternative therapy may be considered if long-term treatment is required. | Not recommended for children and adolescents below 18 years. Safety and effectiveness have not been established. | Generally no dose adjustment is required. Elderly patients may have an increased risk of bleeding and should be monitored carefully. |
Alcohol Constraints
Alcohol may increase the risk of stomach irritation and gastrointestinal bleeding. Limit or avoid alcohol while taking Ticagrelor.
Kidney Impairment Context
No routine dose adjustment is usually required in renal impairment. Use cautiously in patients with severe kidney disease. Monitor renal function when clinically indicated.
Liver Impairment Context
Contraindicated in severe hepatic impairment. Use cautiously in mild to moderate liver disease. Liver function monitoring may be required.
No patient evaluation data has been logged for this metric yet.